Market News AIOpen the app

Akebia Therapeutics has taken out a $140 million loan, starting with $60 million now.

New sharesRead the original at SEC EDGAR
Bad for AKBA

Akebia received cash and replaced its old loan, but the new loan charges at least 11.5% interest and is secured by company assets. Warrants can add shares, so the borrowing costs outweigh the extra cash.

AKBA · Akebia Therapeutics, Inc.

AI read · Bad for AKBA

The AI's read

The new loan gives Akebia some extra cash and replaces old borrowing, but the filing does not say how the old loan’s cost compares. The new loan charges at least 11.5% interest and can reach 15%. The loan is backed by nearly all company assets. Warrants can add shares, early repayment can carry fees, and lenders may reject the extra loan tranches. These costs make the deal unfavorable despite the added cash.

Get alerts for AKBA

Follow Akebia Therapeutics, Inc. (AKBA) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for AKBA
Free on the App Store and Google Play, or on the web.